Halozyme Therapeutics to Acquire Elektrofi, Inc.

Halozyme Acquires Antares Pharma for $960M

April 13, 2022

Pharmaceuticals

Halozyme Therapeutics will acquire Antares Pharma for $5.60 per share in cash, valuing Antares at approximately $960 million. The deal, approved unanimously by both boards, is intended to expand Halozyme's drug delivery capabilities by adding Antares' auto-injector platform and commercial specialty products and is expected to be accretive to Halozyme's 2022 revenue and non-GAAP earnings.

Azelis Agrees to Acquire Haarla Oy

November 18, 2024

Industrial Services

Azelis has signed an agreement to acquire 100% of the shares of Haarla Oy, a Finland-based specialty distributor of food ingredients and industrial chemicals. The acquisition is intended to strengthen Azelis’ position in the Nordics by expanding its product portfolio and customer/principal relationships, with closing expected by the end of 2024 after customary conditions.

Thermo Fisher Scientific Acquires Olink Holding AB

July 10, 2024

Biotechnology

Thermo Fisher Scientific completed the acquisition of Olink Holding AB (publ) via a public cash tender offer at USD 26.00 per share/ADS, buying the proteomics company from shareholders including Summa Equity. The acquisition strengthens Thermo Fisher’s proteomics and protein-analysis capabilities, adding Olink’s high‑multiplex protein detection technology to its life‑science tools portfolio.

Azelis Acquires Hortimex to Expand Food and Nutraceuticals Footprint in Poland

September 26, 2024

Food & Beverage

Azelis has signed an agreement to acquire 100% of the shares of Hortimex, a Poland-based specialty chemicals distributor serving the food ingredients and nutraceuticals markets. The acquisition is intended to strengthen Azelis’ footprint in Poland and complement its Food & Nutrition value chain with a broader local product range and sales/technical capabilities.

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

October 10, 2025

Pharmaceuticals

Akero Therapeutics announced it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a transaction valued at up to $5.2 billion in cash. Under the terms of the deal, Akero shareholders will receive $54.00 per share at closing plus a non-transferable Contingent Value Right (CVR) that could pay an additional $6.00 per share contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis associated with MASH.

Oswaldo Cruz Química Acquires Elekeiroz from H.I.G. Capital

March 23, 2023

Manufacturing

Oswaldo Cruz Química has acquired Elekeiroz from an affiliate of H.I.G. Capital. Elekeiroz, a long-established Brazilian specialty chemicals manufacturer headquartered in Várzea Paulista, São Paulo, was owned by H.I.G. since 2018 and operates production sites in Várzea Paulista and Camaçari.